Related Experiment Video

Updated: May 28, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Bacterial meningitis: current therapy and possible future treatment options

Bianca Woehrl1, Matthias Klein, Denis Grandgirard

  • 1Department of Neurology, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany.

Expert Review of Anti-Infective Therapy
|October 28, 2011
PubMed

Insights

Bacterial meningitis treatment needs improvement due to high fatality and complications. New adjuvant therapies targeting immune response and bacterial lysis are crucial for better outcomes in bacterial meningitis.

Area of Science:

  • Neurology
  • Infectious Diseases
  • Immunology

Background:

  • Bacterial meningitis has high case-fatality and neurologic sequelae rates despite current therapies.
  • Secondary systemic and intracranial complications significantly contribute to poor outcomes.
  • These complications arise from inflammatory responses and pathogen lysis.

Purpose of the Study:

  • To review current bacterial meningitis treatments.
  • To summarize new insights into the pathophysiology of bacterial meningitis.
  • To explore novel adjuvant therapeutic strategies based on experimental models.

Main Methods:

  • Literature review of current treatment strategies.
  • Summary of recent research on bacterial meningitis pathophysiology.
  • Analysis of experimental models for new therapeutic targets.

Main Results:

  • Current targeted therapies are insufficient to reduce high mortality and morbidity.
  • Understanding immune regulation and bacterial lysis mechanisms is key.
  • Adjuvant therapies targeting these mechanisms show promise.

Conclusions:

  • New therapeutic strategies are needed to improve bacterial meningitis outcomes.
  • Focusing on immune modulation and inhibiting bacterial lysis offers potential for adjuvant therapy.
  • Further research and experimental models are vital for developing effective treatments.

More Related Videos

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection05:55

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection

Published on: May 7, 2020

Non-Invasive Model of Neuropathogenic Escherichia coli Infection in the Neonatal Rat08:27

Non-Invasive Model of Neuropathogenic Escherichia coli Infection in the Neonatal Rat

Published on: October 29, 2014

Related Concept Videos

Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Bacterial Meningitis01:24

Bacterial Meningitis

Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Viral Meningitis01:18

Viral Meningitis

Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: